Lupin Share Price Rises As Nomura Stays Positive Amid Patent Litigation
Pharmaceutical major Lupin Ltd.'s share price advanced in early trading hours on Thursday after brokerage firm Nomura maintained a 'buy' call on the company amid its drug patency litigation issue.
The United States District Court for the District of Delaware had ruled in favour of Astellas Pharma, which had raised a patent infringement case against Lupin's generic product 'Mirabegron'.
"The Court noted that the issues of whether Lupin's products infringe the '780 patent, damages, and any additional invalidity theories will be litigated at a consolidated jury trial in 2026," stated an exchange filing on Thursday.
"We believe that there is strong possibility of generics prevailing in this litigation," said a note by Nomura, referring to the generics sold by Indian drugmakers Lupin and Zydus Lifesciences Ltd.
Nomura maintains a positive rating with a target price of Rs 2,350. The brokerage listed two possible cases: a possible restraining order or injunction that prevents generics from selling the product, in which case the earnings per share value estimate for fiscal 2026 may be impacted by 6.7%. They clarified that there is likely no material impact on the next fiscal's estimates though.
In case there is no such restraining order, the brokerage expects generics to continue to sell Mirabegron, with a potential upside to their current estimates.
Brokerage firm UBS holds that generics at-risk sales could be lower now, given the adverse ruling in district court. The next step is for generics to file an appeal to the Federal Court, it said.
Mirabegron is an oral medication which is used to treat overactive bladder. Its benefits are similar to antimuscarinic medication.
Lupin stated that there are no material financial implications. "The company believes it has a strong case and is evaluating further legal action in the matter."
Lupin Share Price Today

Shares of Lupin rose as much as 1.43% to Rs 1,961.90 apiece. It pared gains to trade 0.56% higher at Rs 1,945 apiece, as of 09:52 a.m. This compares to a 0.06% decline in the NSE Nifty 50.
The stock has fallen 17.55% on a year-to-date basis, but risen 20.52% in the last 12 months. The relative strength index was at 45.29.
Out of 37 analysts tracking the company, 22 maintain a 'buy' rating, 10 recommend a 'hold' and five suggest 'sell', according to Bloomberg data. The average 12-month consensus price target of Rs 2,285.06 implies an upside of 17.7%.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.